Integrated Care for the Use of Direct-acting Antivirals in Patients With Chronic Hepatitis C and Substance Use Disorder

2018 ◽  
Vol 12 (5) ◽  
pp. 346-352 ◽  
Author(s):  
Jean-Baptiste Trabut ◽  
Camille Barrault ◽  
Hélène Charlot ◽  
Damien Carmona ◽  
Anne Bourdel ◽  
...  
Keyword(s):  
Substance Use ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Integrated Care ◽  
Chronic Hepatitis C ◽  
Substance Use Disorder ◽  
Direct Acting Antivirals ◽  
Direct Acting

scholarly journals Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

2018 ◽  
Vol 2018 ◽  
pp. 1-10 ◽  
Author(s):  
Sylvia Drazilova ◽  
Martin Janicko ◽  
Lubomir Skladany ◽  
Pavol Kristian ◽  
Marian Oltman ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Systemic Disease ◽  
Direct Acting Antivirals ◽  
Fasting Glycemia ◽  
End Of Treatment ◽  
History Of ◽  
Direct Acting

Background and Aims. Chronic hepatitis C is a systemic disease and type 2 diabetes mellitus (T2DM) belongs to more common extrahepatic. The aim of this study was to (i) explore the prevalence of impaired fasting glucose (IFG) and T2DM in patients with chronic hepatitis C, (ii) explore the effect of direct acting antivirals (DAA) treatment on the glycemia, and (iii) explore the factors that modulate the effect of DAA treatment on glycemia in patients with chronic hepatitis C.Methods. We performed a longitudinal retrospective observational study focused on the patients undergoing DAA treatment of chronic hepatitis C. Data about glycemia, history of diabetes, hepatitis C virus, treatment, and liver status, including elastography, were obtained at baseline (before treatment start), at the end of treatment and 12 weeks after the end of treatment. Patients were treated with various regimens of direct acting antivirals.Results. We included 370 patients; 45.9% had F4 fibrosis. At baseline, the prevalence of T2DM increased with the degree of fibrosis (F0-F2 14.4%, F3 21.3%, and F4 31.8%, p=0.004). Fasting glycemia also increased with the degree of fibrosis (F0-F2 5.75±0.18 F3 5.84±0.17, and F4 6.69±0.2 mmol/L, p=0.001). We saw significant decrease of glycemia after treatment in all patients, but patients without T2DM or IFG from 6.21±0.12 to 6.08±0.15 mmol/L (p=0.002). The decrease was also visible in treatment experienced patients and patients with Child-Pugh A cirrhosis.Conclusion. We confirmed that the prevalence of either T2DM or IFG increases in chronic hepatitis C patients with the degree of fibrosis. The predictive factors for T2DM were, besides F4, fibrosis also higher age and BMI. Significant decrease of fasting glycemia after the DAA treatment was observed in the whole cohort and in subgroups of patients with T2DM, IFG, cirrhotic, and treatment experienced patients.

A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1

2013 ◽  
Vol 59 (1) ◽  
pp. 18-23 ◽  
Author(s):  
Eric Lawitz ◽  
Fred Poordad ◽  
Kris V. Kowdley ◽  
Daniel E. Cohen ◽  
Thomas Podsadecki ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Genotype 1 ◽  
Direct Acting Antivirals ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document